AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 6:56 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 6:56 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
UnitedHealth Group (UNH) Ties Up to Aid Medicare Members
by Zacks Equity Research
UnitedHealth Group (UNH) teams up with Walmart to follow a collaborative approach in extending advanced healthcare services to Medicare members at specific Walmart Health locations.
Abbott (ABT) Debuts Amplatzer Talisman System in Europe
by Zacks Equity Research
Abbott's (ABT) Amplatzer Talisman PFO Occlusion System will enable doctors across Europe to treat people experiencing a patent foramen ovale-associated stroke.
Accuray's (ARAY) Latest Collaboration to Improve Patient Care
by Zacks Equity Research
Accuray (ARAY) partners with Genolier Innovation Hub to unite companies from the MedTech, pharma and biosciences sectors with physicians and scientists for better patient outcomes.
Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
by Zacks Equity Research
Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.
Quest Diagnostics (DGX) Stock Gains on EUA for Monkeypox Test
by Zacks Equity Research
According to Quest Diagnostics (DGX), this test can differentiate monkeypox viral DNA from other non-variola orthopoxviruses in a specimen, helping to enable a faster final diagnosis.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Edward Lifesciences (EW) Gains From New Products Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Boston Scientific's (BSX) WATCHMAN FLX to Offer DAPT in the US
by Zacks Equity Research
Boston Scientific (BSX) to offer updated labeling for WATCHMAN FLX device after receiving FDA approval.
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.
Zacks.com featured highlights include Marubeni, AMN Healthcare Services, Veritiv and Universal Logistics Holdings
by Zacks Equity Research
Marubeni, AMN Healthcare Services, Veritiv and Universal Logistics Holdings are part of Zacks Screen of the Week article.
Factors that Make Humana (HUM) an Attractive Bet Now
by Zacks Equity Research
Humana (HUM) continues to gain on continued top-line growth resulting from its solid Medicaid and Medicare businesses. A strong cash position enables HUM to undertake growth-related investments.
SmileDirectClub (SDC) Faces Low Aligner Shipment, Margin Woe
by Zacks Equity Research
The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
CVS Health (CVS) to Buy Signify Health, Grow in Home Healthcare
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, as a leading healthcare platform, will play a critical role in advancing the company's healthcare services strategy.
Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care
by Zacks Equity Research
Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.
Here's Why You Should Hold on to BD (BDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
Scoop Up Big Gains With 4 Stocks Witnessing Rise in Cash Flow
by Moumita C. Chattopadhyay
Cash is the lifeblood of any business and provides strength to a company and so MARUY, AMN, VRTV and ULH are worth buying.
Zacks.com featured highlights include Industrias Bachoco S.A.B. de C.V., AMN Healthcare, Veritiv and CONSOL Energy
by Zacks Equity Research
Industrias Bachoco S.A.B. de C.V., AMN Healthcare, Veritiv and CONSOL Energy are part of Zacks Screen of the Week article.
Humana (HUM) Brings Home Health Unit of KAH Under CenterWell
by Zacks Equity Research
Humana (HUM) wraps up rebranding KAH's home health operations to the CenterWell brand. This leads to the clubbing of HUM's three payer-agnostic care services into a common suite.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) segmental results and robust bookings and backlog growth.
Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight
by Zacks Equity Research
Zimmer Biomet's (ZBH) HipInsight is a mixed reality-based visualization tool that will aid surgeons in precise implant placement and alignment during total hip replacement.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
Masimo's (MASI) Latest Watch to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) full-market consumer release of the Masimo W1 and other related launches is likely to significantly improve RPM.